deferasirox:
Showing 1 - 25 of 54
Beta-thalassemia, Iron Overload Trial in Los Angeles, Oakland, Chicago (Deferasirox)
Completed
- Beta-thalassemia
- Iron Overload
-
Los Angeles, California
- +2 more
Jun 8, 2021
MDS, Iron Overload Trial in Stanford, Detroit, Houston (Deferasirox)
Completed
- Myelodysplastic Syndromes
- Iron Overload
-
Stanford, California
- +2 more
Jun 1, 2021
Transfusional Iron Overload, Iron Overload, Iron Chelation Trial (SPD602, Deferasirox)
Withdrawn
- Transfusional Iron Overload
- +6 more
- (no location specified)
Jun 1, 2021
ß-thalassemia, Transfusional Iron Overload Trial in Cagliari, Genova, Orbassano (Deferasirox)
Completed
- β-thalassemia
- Transfusional Iron Overload
-
Cagliari, CA, Italy
- +2 more
Dec 6, 2020
Chronic Iron Overload Trial in Worldwide (Deferiprone, Deferasirox)
Completed
- Chronic Iron Overload
-
Lushnjë, Albania
- +21 more
Apr 8, 2021
Anemia, Myelodysplastic Syndrome Trial in Seattle (Deferasirox, Laboratory Biomarker Analysis)
Terminated
- Anemia
- Myelodysplastic Syndrome
- Deferasirox
- Laboratory Biomarker Analysis
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 12, 2020
Myelodysplastic Syndrome, Iron Overload Trial in Canada, United States (Deferasirox)
Completed
- Myelodysplastic Syndrome
- Iron Overload
-
Birmingham, Alabama
- +47 more
Jul 21, 2021
Acute Myeloid Leukemia Trial in Maywood (Deferasirox, Cholecalciferol, Azacitidine)
Terminated
- Acute Myeloid Leukemia
- Deferasirox
- +2 more
-
Maywood, IllinoisLoyola University Cardinal Bernardin Cancer Center
Feb 25, 2020
Transfusion-dependent ß-thalassemia Patients, Cardiac Iron Overload Trial in Athens, Patras (Deferasirox, Deferoxamine (DFO))
Terminated
- Transfusion-dependent β-thalassemia Patients
- Cardiac Iron Overload
- Deferasirox
- Deferoxamine (DFO)
-
Athens, GR, Greece
- +3 more
Oct 21, 2019
Non-transfusion Dependent Thalassemia Trial in Worldwide (deferasirox)
Completed
- Non-transfusion Dependent Thalassemia
-
Nanning, Guangxi, China
- +10 more
Sep 19, 2019
Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease Trial in Boston (Deferoxamine, Deferasirox, HIDA)
Completed
- Transfusion-dependent Hemachromatosis
- +2 more
- Deferoxamine
- +2 more
-
Boston, MassachusettsChildren's Hospital Boston
Jun 14, 2019
MDS Trial in Worldwide (Deferasirox, Placebo)
Myelodysplastic Syndrome Trial in Liege (Bone marrow aspirate, Deferasirox)
Terminated
- Myelodysplastic Syndrome
- Bone marrow aspirate
- Deferasirox
-
Liege, BelgiumNovartis Investigative Site
Jul 24, 2018
Breast Cancer, Iron Overload, Leukemia Trial in Minneapolis (deferasirox)
Terminated
- Breast Cancer
- +7 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Dec 3, 2017
Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD Trial (Deferasirox)
Withdrawn
- Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
- (no location specified)
Apr 19, 2017
Transfusional Iron Overload, ß-thalassemia Major, Pediatric Rare Anemia Trial in France, Italy (Deferasirox)
Completed
- Transfusional Iron Overload
- +2 more
-
Lyon, France
- +3 more
Feb 12, 2017
MDS, Beta-Thalassemia Trial in Hungary (deferasirox)
Completed
- Myelodysplastic Syndromes
- Beta-Thalassemia
-
Budapest, Hungary
- +3 more
Feb 22, 2017